Drug targets for COVID-19 therapeutics: Ongoing global efforts
Author:
Open Access
- 29 June 2020
- journal article
- review article
- Published by Springer Nature in Journal of Biosciences
- Vol. 45 (1) , 1-24
Abstract
The current global pandemic COVID-19 caused by the SARS-CoV-2 virus has already inflicted insurmountable damage both to the human lives and global economy. There is an immediate need for identification of effective drugs to contain the disastrous virus outbreak. Global efforts are already underway at a war footing to identify the best drug combination to address the disease. In this review, an attempt has been made to understand the SARS-CoV-2 life cycle, and based on this information potential druggable targets against SARS-CoV-2 are summarized. Also, the strategies for ongoing and future drug discovery against the SARS-CoV-2 virus are outlined. Given the urgency to find a definitive cure, ongoing drug repurposing efforts being carried out by various organizations are also described. The unprecedented crisis requires extraordinary efforts from the scientific community to effectively address the issue and prevent further loss of human lives and health.Keywords
This publication has 323 references indexed in Scilit:
- Suppression of Coronavirus Replication by Cyclophilin InhibitorsViruses, 2013
- The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extensionNucleic Acids Research, 2011
- Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel DiseaseScience Translational Medicine, 2011
- Exploiting drug-disease relationships for computational drug repositioningBriefings in Bioinformatics, 2011
- Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusionVirology, 2011
- Effects of Air Temperature and Relative Humidity on Coronavirus Survival on SurfacesApplied and Environmental Microbiology, 2010
- Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2Journal of General Virology, 2008
- Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic miceVirology, 2008
- SARS coronavirus accessory proteinsVirus Research, 2008
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004